Boryung Pharm challenges KRW 240 billion sales with the antihypertensive ‘Kanarb’
Boryung Pharm will challenge KRW 240 sales with ‘Kanarb(antihypertensive),’ the 15th domestic new drug, by 2020.
According to Boryung Pharm, the company is planning to expand its domestic and foreign markets with various complexes, such as CCB and hyperlipidemia complexes, starting with ‘Kanarb ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
